[ Price : $8.95]
Novartis files a supplemental BLA for Kymriah (tisagenlecleucel) suspension for intravenous infusion for treating adult patients w...[ Price : $8.95]
Federal Register notice: FDA seeks comments on an information collection extension on Postmarketing Safety Reports for Human Drug ...[ Price : $8.95]
Federal Register notice: FDA makes available a guidance entitled Manufacturers Sharing Patient-Specific Information from Medical D...[ Price : $8.95]
FDA warns Indias Kim Chemicals about CGMP and other violations in its manufacturing of OTC products.[ Price : $8.95]
An FDA safety update says that interim study results from a pivotal clinical trial continue to show an increased rate of major adv...[ Price : $8.95]
FDA warns Accelerated Analytical Laboratories about CGMP violations at its drug manufacturing facility.[ Price : $8.95]
FDA says it will recognize drug manufacturing inspections from eight European countries, avoiding duplication of inspections and r...[ Price : $8.95]
As a condition of approval, FDA is requiring that AstraZeneca conduct additional studies to verify and describe anticipated clinic...